

Ref: FOI/GS/ID 6716

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

10 June 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to biologic drugs.

You asked:

Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- a. Adalimumab - Humira*
- b. Adalimumab Biosimilar*
- c. Apremilast*
- d. Brodalumab*
- e. Certolizumab*
- f. Dimethyl fumarate*
- g. Etanercept - Enbrel*
- h. Etanercept Biosimilar*
- i. Guselkumab*
- j. Infliximab - Remicade*
- k. Infliximab Biosimilar*
- l. Ixekizumab*
- m. Risankizumab*
- n. Secukinumab*
- o. Tildrakizumab*
- p. Ustekinumab*

Q2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?

Q3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- a. Adalimumab - Humira*

- b. *Adalimumab Biosimilar*
- c. *Golimumab*
- d. *Infliximab - Remicade*
- e. *Infliximab Biosimilar*
- f. *Tofacitinib*
- g. *Ustekinumab*
- h. *Vedolizumab*

Trust response:

Maidstone and Tunbridge Wells NHS Trust is not a dermatology centre so we are unable to answer Q's 1+2.

Please note: Figures are for February to April 2021 inclusive

Q3.

- a. 19
- b. 168
- c. 0
- d. 0
- e. 116
- f. 10
- g. 33
- h. 92